SCHEMBL6848356

SCHEMBL6848356

COC(=O)c1cncc(CCc2cccc(C(=O)Nc3cccc(N4CCN(C(=O)OC(C)(C)C)CC4)c3C(F)(F)F)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
TSHR P16473 3/20 0.41
HSD17B10 Q99714 1/20 0.41
LIPG Q9Y5X9 1/20 0.40
ACKR3 P25106 1/20 0.39
MET P08581 1/20 0.39
BACE1 P56817 3/20 0.39
GAA P10253 1/20 0.39
MAPK8 P45983 1/20 0.38
REV1 Q9UBZ9 1/20 0.38
WDR5 P61964 1/20 0.38
ATM Q13315 1/20 0.38
SCD O00767 1/20 0.37
SCD5 Q86SK9 1/20 0.37
ABCB1 P08183 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
GFER P55789 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6848352 0.88 ALDH1A1 (0.40) ALDH1A1LIPGACKR3METBACE1
SCHEMBL6846514 0.85 TSHR (0.42) ALDH1A1TSHRHSD17B10LIPGMET
SCHEMBL6844797 0.84 MET (0.39) ALDH1A1TSHRHSD17B10LIPGMET
SCHEMBL6841382 0.84 WNT3A (0.41) ALDH1A1TSHRHSD17B10LIPGMET
SCHEMBL6846441 0.80 TSHR (0.47) ALDH1A1TSHRHSD17B10BACE1MAPK8
SCHEMBL6844775 0.79 LIPG (0.41) LIPGMETSCDSCD5
SCHEMBL6844798 0.79 LIPG (0.39) LIPGMET
SCHEMBL6844706 0.77 BACE1 (0.40) ALDH1A1TSHRHSD17B10BACE1GAA
SCHEMBL6846606 0.76 BACE1 (0.44) ALDH1A1TSHRHSD17B10BACE1MAPK8
SCHEMBL6846841 0.75 HTT (0.37) ALDH1A1TSHRHSD17B10LIPGMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA ALDH1A1 3632/4885TSHR 2259/4885HSD17B10 3952/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA ALDH1A1 3632/4885TSHR 2259/4885HSD17B10 3952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.